Summary

Even when AI designs molecules with potential as medicines, drug development can be delayed if the process of producing them is slow. KAIST researchers have developed an "unmanned synthesis platform" that uses synthesis robots and light to automatically carry out the entire process from mixing raw materials to synthesis and analysis. The technology is expected to help secure a wider range of drug candidate compounds by reducing the burden of repetitive experiments.

AI summaries can be wrong sometimes—always verify important details using the source article.